List of Duaklir Pressair drug patents

Duaklir Pressair is owned by Astrazeneca.

Duaklir Pressair contains Aclidinium Bromide; Formoterol Fumarate.

Duaklir Pressair has a total of 5 drug patents out of which 1 drug patent has expired.

Expired drug patents of Duaklir Pressair are:

  • US6681768

Duaklir Pressair was authorised for market use on 29 March, 2019.

Duaklir Pressair is available in powder, metered;inhalation dosage forms.

Duaklir Pressair can be used as maintenance treatment of chronic obstructive pulmonary disease (copd).

The generics of Duaklir Pressair are possible to be released after 13 March, 2029.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE46417 ASTRAZENECA Quinuclidine derivatives and their use as muscarinic M3 receptor ligands
Feb, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6681768 ASTRAZENECA Powder formulation disintegrating system and method for dry powder inhalers
Aug, 2022

(5 months ago)

US8051851 ASTRAZENECA Inhaler for the administration of powdered pharmaceuticals, and a powder cartridge system for use with this inhaler
Apr, 2027

(4 years from now)

US10085974 ASTRAZENECA Dosage and formulation
Mar, 2029

(6 years from now)

US11000517 ASTRAZENECA Dosage and formulation
Mar, 2029

(6 years from now)

Exclusivity Exclusivity Expiration
New Combination (NC) Mar 29, 2022

Drugs and Companies using ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE ingredient

Market Authorisation Date: 29 March, 2019

Treatment: Maintenance treatment of chronic obstructive pulmonary disease (copd)

Dosage: POWDER, METERED;INHALATION

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in